Shilpa Medicare Backs US Biotech Alveolus Bio to Accelerate Next‐Gen Lung Disease Therapies

Shilpa Medicare Limited (BSE: 524742, NSE: SHILPAMED), one of India's leading pharmaceutical companies known for its end‐to‐end solutions in new biological entity (NBE) development, today announced a strategic lead investment in US‐based Alveolus Bio, Inc., a biotech startup advancing inhaled live biotherapeutics and small molecule therapies for chronic and life‐threatening lung diseases.

Under this strategic engagement, Shilpa Biologics Private Limited - the biologics arm of Shilpa Medicare - will additionally serve asthe exclusive global development and manufacturing partner for Alveolus Bio, reinforcing Shilpa's capabilities for global CDMO projects.

This collaboration reinforces India's growing role in global biotech innovation by combining Shilpa's expertise in turnkey biologics development, process optimization, and manufacturing with Alveolus Bio's cutting‐edge resMIT platform, which engineers inhalable live therapeutics to address hard‐to‐treat respiratory conditions like COPD, Bronchopulmonary Dysplasia, and Pulmonary Fibrosis.

"Shilpa Medicare has always been at the forefront of enabling breakthrough biologics with our world‐class development and manufacturing capabilities," said Vishnukant Bhutada, Managing Director, Shilpa Medicare Limited. "This partnership with Alveolus Bio not only strengthens our innovation pipeline but also positions Shilpa as a key global partner for biotech companies looking to translate bold science into scalable clinical and commercial solutions."

The investment will fund Alveolus Bio's lead COPD program through Phase 2 clinical trials and accelerate additional preclinical programs. Importantly, the collaboration also creates a platform for co‐development and future manufacturing partnerships, potentially leveraging India's competitive biologics manufacturing ecosystem for global clinical and commercial supply.

"This partnership with Shilpa Medicare is not just about funding-it's about combining deep biotech innovation with proven pharmaceutical execution," said Gaurav Mehta, CEO of Alveolus Bio. "Together, we can deliver these life‐changing therapies to patients much faster and more efficiently."

The move aligns with Shilpa's strategy to expand its biologics footprint, diversify into innovative therapeutic platforms, and build strategic alliances with disruptive biotech companies globally.

"The science at Alveolus Bio represents a paradigm shift in respiratory medicine," added Dr. C. Vivek Lal, Founder and Chief Scientific Officer of Alveolus Bio. "This partnership seamlessly bridges cutting‐edge biotech innovation with Shilpa's global pharmaceutical leadership, enabling rapid clinical translation of our novel therapies."

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 907.00 as compared to the previous close of Rs. 905.50. The total number of shares traded during the day was 6855 in over 311 trades.

The stock hit an intraday high of Rs. 922.00 and intraday low of 891.30. The net turnover during the day was Rs. 6201547.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Pharmaceuticals USBiotech AlveolusBio